Advertisement

Coagulopathies and Hypercoagulable States

  • Aaron Strumwasser
  • Erin Palm
Chapter

Abstract

Coagulopathy management in the surgical ICU (SICU) requires early recognition and rapid treatment of the underlying hemostatic disturbance. The degree of prothrombotic and/or antithrombotic tendency can be assessed by conventional coagulation testing (PT/PTT/INR), but recent literature suggests that point-of-care viscoelastic testing (TEG/ROTEM) may allow for more rapid, accurate, and timely diagnosis and treatment. While acquired states of coagulopathy due to traumatic bleeding or postoperative hemorrhage are more common in the SICU, the surgical intensivist must be able to identify and treat the commonly inherited coagulopathies in the ICU: heparin-induced thrombocytopenia (HIT), von Willebrand disease (VWD), hemophilia, and clotting factor deficiencies.

Keywords

Coagulopathy Bleeding HIT Hemophilia VWD Viscoelastic testing 

References

  1. 1.
    Levi M, Opal SM. Coagulation abnormalities in critically ill patients. Crit Care. 2006;10:222.CrossRefGoogle Scholar
  2. 2.
    Vanderschueren S, De Weerdt A, Malbrain M. Thrombocytopenia and prognosis in intensive care. Crit Care Med. 2000;28:1871–6.CrossRefGoogle Scholar
  3. 3.
    Ahmed A, Kojicic M, Herasevich V, Gajic O. Early identification of patients with or at risk of acute lung injury. Neth J Med. 2009;67:268–71.PubMedGoogle Scholar
  4. 4.
    Schultz MJ. Early recognition of critically ill patients. Neth J Med. 2009;67:266–7.PubMedGoogle Scholar
  5. 5.
    Whiting P, Al M, Westwood M, Ramos IC, Ryder S, Armstrong N, Misso K, Ross J, Severens J, Kleijnen J. Viscoelastic point-of-care testing to assist with the diagnosis, management and monitoring of haemostasis: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2015;19(58):1–228.CrossRefGoogle Scholar
  6. 6.
    Levy JH, Faraoni D, Sniecinski RM. Perioperative coagulation management in the intensive care unit. Curr Opin Anaesthesiol. 2013;26(1):65–70.CrossRefGoogle Scholar
  7. 7.
    Coutre S, Leung L, Tirnauer JS. Clinical presentation and diagnosis of heparin-induced thrombocytopenia. UpToDate Online. Nov 02, 2016.Google Scholar
  8. 8.
    Warkentin TE, Sheppard JA, Sigouin CS, Kohlmann T, Eichler P, Greinacher A. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood. 2006;108(9):2937.CrossRefGoogle Scholar
  9. 9.
    Stein PD, Hull RD, Matta F, Yaekoub AY, Liang J. Incidence of thrombocytopenia in hospitalized patients with venous thromboembolism. Am J Med. 2009;122(10):919.CrossRefGoogle Scholar
  10. 10.
    Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia and thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest. 1994;93(1):81.CrossRefGoogle Scholar
  11. 11.
    Rauova L, Zhai L, Kowalska MA, Arepally GM, Cines DB, Poncz M. Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. Blood. 2006;107(6):2346.CrossRefGoogle Scholar
  12. 12.
    Kelton JG, Smith JW, Warkentin TE, Hayward CP, Denomme GA, Horsewood P. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood. 1994;83(11):3232.PubMedGoogle Scholar
  13. 13.
    Rauova L, Poncz M, McKenzie SE, Reilly MP, Arepally G, Weisel JW, Nagaswami C, Cines DB, Sachais BS. Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood. 2005;105(1):131.CrossRefGoogle Scholar
  14. 14.
    Khandelwal S, Arepally GM. Immune pathogenesis of heparin-induced thrombocytopenia. Thromb Haemost. 2016;116(5):792–8.CrossRefGoogle Scholar
  15. 15.
    Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood. 2005;106(8):2710.CrossRefGoogle Scholar
  16. 16.
    Girolami B, Prandoni P, Stefani PM, Tanduo C, Sabbion P, Eichler P, Ramon R, Baggio G, Fabris F, Girolami A. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood. 2003;101(8):2955.CrossRefGoogle Scholar
  17. 17.
    Warkentin TE, Makris M, Jay RM, Kelton JG. A spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia. Am J Med. 2008;121(7):632.CrossRefGoogle Scholar
  18. 18.
    Krauel K, Pötschke C, Weber C, Kessler W, Fürll B, Ittermann T, Maier S, Hammerschmidt S, Bröker BM, Greinacher A. Platelet factor 4 binds to bacteria, [corrected]inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia. Blood. 2011;117(4):1370.CrossRefGoogle Scholar
  19. 19.
    Greinacher A, Holtfreter B, Krauel K, Gätke D, Weber C, Ittermann T, Hammerschmidt S, Kocher T. Association of natural anti-platelet factor 4/heparin antibodies with periodontal disease. Blood. 2011;118(5):1395.CrossRefGoogle Scholar
  20. 20.
    Warkentin TE, Basciano PA, Knopman J, Bernstein RA. Spontaneous heparin-induced thrombocytopenia syndrome: 2 new cases and a proposal for defining this disorder. Blood. 2014;123(23):3651.CrossRefGoogle Scholar
  21. 21.
    Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S, Crowther M. American College of Chest Physicians. Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e495S.CrossRefGoogle Scholar
  22. 22.
    Warkentin TE, Sheppard JA, Horsewood P, et al. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood. 2000;96:1703.PubMedGoogle Scholar
  23. 23.
    Prandoni P, Siragusa S, Girolami B, Fabris F, BELZONI Investigators Group. The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study. Blood. 2005;106(9):3049.CrossRefGoogle Scholar
  24. 24.
    Warkentin TE. Heparin-induced thrombocytopenia: a clinicopathologic syndrome. Thromb Haemost. 1999;82(2):439.PubMedGoogle Scholar
  25. 25.
    Warkentin TE. Clinical presentation of heparin-induced thrombocytopenia. Semin Hematol. 1998;35(4 Suppl 5):9.PubMedGoogle Scholar
  26. 26.
    Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 2001;344(17):1286.CrossRefGoogle Scholar
  27. 27.
    Lubenow N, Kempf R, Eichner A, Eichler P, Carlsson LE, Greinacher A. Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin. Chest. 2002;122(1):37.CrossRefGoogle Scholar
  28. 28.
    Hong AP, Cook DJ, Sigouin CS, Warkentin TE. Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia. Blood. 2003;101(8):3049.CrossRefGoogle Scholar
  29. 29.
    LaMonte MP, Brown PM, Hursting MJ. Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy. Crit Care Med. 2004;32(4):976.CrossRefGoogle Scholar
  30. 30.
    Giossi A, Del Zotto E, Volonghi I, Costa P, Bertuetti R, Remida P, Magoni M, Gasparotti R, Padovani A, Pezzini A. Thromboembolic complications of heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis. 2012;23(6):559.CrossRefGoogle Scholar
  31. 31.
    Rosenberger LH, Smith PW, Sawyer RG, Hanks JB, Adams RB, Hedrick TL. Bilateral adrenal hemorrhage: the unrecognized cause of hemodynamic collapse associated with heparin-induced thrombocytopenia. Crit Care Med. 2011;39(4):833.CrossRefGoogle Scholar
  32. 32.
    Thota R, Porter J, Ganti AK, Peters E. Hemodynamic collapse following bilateral knee arthroplasty: a mysterious case. J Thromb Thrombolysis. 2012;33(1):3–5.CrossRefGoogle Scholar
  33. 33.
    Goel R, Ness PM, Takemoto CM, Krishnamurti L, King KE, Tobian AA. Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality. Blood. 2015;125(9):1470.CrossRefGoogle Scholar
  34. 34.
  35. 35.
    Nagler M, Bachmann LM, ten Cate H, ten Cate-Hoek A. Diagnostic value of immunoassays for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood. 2016;127(5):546.CrossRefGoogle Scholar
  36. 36.
    Nagler M, Bakchoul T. Clinical and laboratory tests for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost. 2016;116(5):823–34.CrossRefGoogle Scholar
  37. 37.
    Asmis LM, Segal JB, Plantinga LC, Fink NE, Kerman JS, Kickler TS, Coresh J, Gardner LB. Heparin-induced antibodies and cardiovascular risk in patients on dialysis. Thromb Haemost. 2008;100(3):498.PubMedGoogle Scholar
  38. 38.
    Kouerinis IA, El-Ali M, Theakos N, Dedeilias P. Can thromboelastography predict which patients with heparin-induced thrombocytopenia may suffer thrombotic complications of type II? Eur J Cardiothorac Surg. 2007;32(3):544–6.CrossRefGoogle Scholar
  39. 39.
    Iwanski J, Kazui T, Le Tran P, Basken R, Wong RK, Khalpey Z. Novel method using rotational thromboelastography analysis for intraoperative management of device patient with heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis. 2016;27(8):943–7.CrossRefGoogle Scholar
  40. 40.
    Haeberle HA, Menzel D, Unertl K, Nohé B. Management of complex thrombocytopenia with thrombelastometry : a case of simultaneous posttransfusion purpura and heparin-induced thrombocytopenia. Anaesthesist. 2011;60(12):1135–40.CrossRefGoogle Scholar
  41. 41.
    Marks PW. Coagulation disorders in the ICU. Clin Chest Med. 2009;30(1):123–9.CrossRefGoogle Scholar
  42. 42.
    Coutre S, Leung L, Tirnauer JS. Management of heparin-induced thrombocytopenia. UpToDate Online. Nov 02, 2016.Google Scholar
  43. 43.
    Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996;101(5):502.CrossRefGoogle Scholar
  44. 44.
    Wallis DE, Workman DL, Lewis BE, Steen L, Pifarre R, Moran JF. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med. 1999;106(6):629.CrossRefGoogle Scholar
  45. 45.
    Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG, Argatroban-915 Investigators. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med. 2003;163(15):1849.CrossRefGoogle Scholar
  46. 46.
    Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, Fareed J, Walenga JM, Bartholomew J, Sham R, Lerner RG, Zeigler ZR, Rustagi PK, Jang IK, Rifkin SD, Moran J, Hursting MJ, Kelton JG, ARG-911 Study Investigators. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. 2001;103(14):1838.CrossRefGoogle Scholar
  47. 47.
    Lewis BE, Wallis DE, Hursting MJ, Levine RL, Leya F. Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia. Chest. 2006;129(6):1407.CrossRefGoogle Scholar
  48. 48.
    Nichols W, Hultin M, James A, et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the national heart, lung, and blood institute (NHLBI) expert panel report (USA). Haemophilia. 2008;14:171–232.CrossRefGoogle Scholar
  49. 49.
    Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand’s disease. Blood. 1987;69:454–9.PubMedGoogle Scholar
  50. 50.
    Lillicrap D. von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy. Hematol Am Soc Hematol Educ Program. 2013;2013:254–60.Google Scholar
  51. 51.
    Sadler JE, Budde U, Eikenboom JC, et al. Working party on von Willebrand disease classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand factor. J Thromb Haemost. 2006;4:2103–14.CrossRefGoogle Scholar
  52. 52.
    Kouides PA, Phatak PD, Burkart P, et al. Gynaecological and obstetrical morbidity in women with type I von Willebrand disease: results of a patient survey. Haemophilia. 2000;6:643–8.CrossRefGoogle Scholar
  53. 53.
    Federici A, Bucciarelli P, Castaman G, et al. The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease: a prospective cohort study of 796 cases. Blood. 2014;123:4037–44.CrossRefGoogle Scholar
  54. 54.
    Neff AT. Current controversies in the diagnosis and management of von Willebrand disease. Ther Adv Hematol. 2015;6(4):209–16.CrossRefGoogle Scholar
  55. 55.
    Bucciarelli P, Siboni S, Stufano F, et al. Predictors of von Willebrand disease diagnosis in individuals with borderline von Willebrand factor plasma levels. J Thromb Haemost. 2015;13:228–36.CrossRefGoogle Scholar
  56. 56.
    Stolla M, Chang S, Schulman S, Bauer K, Haspel R, Lerner AB. Use of thromboelastography in the management of a patient with acquired von Willebrand disease undergoing cardiac bypass surgery. Br J Haematol. 2017.Google Scholar
  57. 57.
    Schmidt DE, Majeed A, Bruzelius M, Odeberg J, Holmström M, Ågren A. A prospective diagnostic accuracy study evaluating rotational thromboelastometry and thromboelastography in 100 patients with von Willebrand disease. Haemophilia. 2016;23(2):309–18.CrossRefGoogle Scholar
  58. 58.
    Svensson P, Bergqvist P, Juul K, Berntorp E. Desmopressin in treatment of haematological disorders and in prevention of surgical bleeding. Blood Rev. 2014;28:95–102.CrossRefGoogle Scholar
  59. 59.
    Federici A, Mazurier C, Berntorp E, et al. Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. Blood. 2004;103:2032–8.CrossRefGoogle Scholar
  60. 60.
    Rodeghiero F, Castaman G, Di Bona E, et al. Consistency of responses to repeated DDAVP infusions in patients with von Willebrand’s disease and hemophilia A. Blood. 1989;74:199–200.Google Scholar
  61. 61.
    Mannucci PM, Chediak J, Hanna W, et al. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood. 2002;99:450–6.CrossRefGoogle Scholar
  62. 62.
    Abshire T, Federici A, Alvarez M, et al. Prophylaxis in severe forms of von Willebrand’s disease: results from the von Willebrand disease prophylaxis network (VWD PN). Haemophilia. 2013;19:76–81.CrossRefGoogle Scholar
  63. 63.
    Sumner M, Williams J. Type 3 von Willebrand disease: assessment of complications and approaches to treatment – results of a patient and hemophilia treatment center survey in the United States. Haemophilia. 2004;10:360–6.CrossRefGoogle Scholar
  64. 64.
    Hoots KW, Shapiro AD. Clinical manifestations and diagnosis of hemophilia. UpToDate Nov 11, 2014.Google Scholar
  65. 65.
    Ruiz-Saez A. Occurrence of thrombosis in rare bleeding disorders. Semin Thromb Hemost. 2013;39(6):684–92. Epub 2013 Aug 8. [Giansily-Blaizot M, Biron-Andreani C, Aguilar-Martinez P, de Moeloose P, Briquel ME, Goudemand J, Stieltjes N, Barrot C, Chambost H, Durin A, Gay V, Peynet J, Pouymayou K, Schved JF. Inherited factor VII deficiency and surgery: clinical data are the best criteria to predict the risk of bleeding. Br J Haematol. 2002;117(1):172].CrossRefGoogle Scholar
  66. 66.
    Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood. 2004;104(5):1243.CrossRefGoogle Scholar
  67. 67.
    Acharya SS, Coughlin A, Dimichele DM, North American Rare Bleeding Disorder Study Group. Rare Bleeding Disorder Registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias. J Thromb Haemost. 2004;2(2):248.CrossRefGoogle Scholar
  68. 68.
    Hanss M, Biot F. A database for human fibrinogen variants. Ann N Y Acad Sci. 2001;936:89.CrossRefGoogle Scholar
  69. 69.
    Peyvandi F, Palla R, Menegatti M, Siboni SM, Halimeh S, Faeser B, Pergantou H, Platokouki H, Giangrande P, Peerlinck K, Celkan T, Ozdemir N, Bidlingmaier C, Ingerslev J, Giansily-Blaizot M, Schved JF, Gilmore R, Gadisseur A, Benedik-Dolničar M, Kitanovski L, Mikovic D, Musallam KM, Rosendaal FR, European Network of Rare Bleeding Disorders Group. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost. 2012;10(4):615–21.CrossRefGoogle Scholar
  70. 70.
    Giansily-Blaizot M, Biron-Andreani C, Aguilar-Martinez P, de Moeloose P, Briquel ME, Goudemand J, Stieltjes N, Barrot C, Chambost H, Durin A, Gay V, Peynet J, Pouymayou K, Schved JF. Inherited factor VII deficiency and surgery: clinical data are the best criteria to predict the risk of bleeding. Br J Haematol. 2002;117(1):172. [Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood. 2004;104(5):1243].CrossRefGoogle Scholar
  71. 71.
    Girolami A, Sartori MT, Simioni P. An updated classification of factor XIII defect. Br J Haematol. 1991;77(4):565.CrossRefGoogle Scholar
  72. 72.
    Nogami K. The utility of thromboelastography in inherited and acquired bleeding disorders. Br J Haematol. 2016;174(4):503–14.CrossRefGoogle Scholar
  73. 73.
    Al Hawaj MA, Martin EJ, Venitz J, Barrett JC, Kuhn JG, Nolte ME, Brophy DF. Monitoring rFVIII prophylaxis dosing using global haemostasis assays. Haemophilia. 2013;19(3):409–14.CrossRefGoogle Scholar
  74. 74.
    Fowler H, Lacey R, Keaney J, Kay-Jones C, Martlew V, Thachil J. Emergency and out of hours care of patients with inherited bleeding disorders. Haemophilia. 2012;18(3):e126–31.CrossRefGoogle Scholar
  75. 75.
    Hoots WK. Emergency management in hemophilia. In: Lee CA, Berntorp EE, Hoots WK, editors. Textbook of hemophilia. 2nd ed. Oxford, UK: Wiley-Blackwell; 2010. p. 394.CrossRefGoogle Scholar
  76. 76.
    Schulman S, Varon D, Keller N, Gitel S, Martinowitz U. Monoclonal purified F VIII for continuous infusion: stability, microbiological safety and clinical experience. Thromb Haemost. 1994;72(3):403.PubMedGoogle Scholar
  77. 77.
    Martinowitz UP, Schulman S. Continuous infusion of factor concentrates: review of use in hemophilia A and demonstration of safety and efficacy in hemophilia B. Acta Haematol. 1995;94(Suppl 1):35.CrossRefGoogle Scholar
  78. 78.
    Hay CR, Doughty HI, Savidge GF. Continuous infusion of factor VIII for surgery and major bleeding. Blood Coagul Fibrinolysis. 1996;7(Suppl 1):S15.PubMedGoogle Scholar
  79. 79.
    Schulman S, Wallensten R, White B, Smith OP. Efficacy of a high purity, chemically treated and nanofiltered factor IX concentrate for continuous infusion in haemophilia patients undergoing surgery. Haemophilia. 1999;5(2):96.CrossRefGoogle Scholar
  80. 80.
    Paton RW, Evans DI. Silent avascular necrosis of the femoral head in haemophilia. J Bone Joint Surg Br. 1988;70(5):737.CrossRefGoogle Scholar
  81. 81.
    Kisker CT, Burke C. Double-blind studies on the use of steroids in the treatment of acute hemarthrosis in patients with hemophilia. N Engl J Med. 1970;282(12):639.CrossRefGoogle Scholar
  82. 82.
    Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, Ingram JD, Manco-Johnson ML, Funk S, Jacobson L, Valentino LA, Hoots WK, Buchanan GR, DiMichele D, Recht M, Brown D, Leissinger C, Bleak S, Cohen A, Mathew P, Matsunaga A, Medeiros D, Nugent D, Thomas GA, Thompson AA, McRedmond K, Soucie JM, Austin H, Evatt BL. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357(6):535.CrossRefGoogle Scholar
  83. 83.
    Franchini M, Favaloro EJ, Lippi G. Mild hemophilia A. J Thromb Haemost. 2010;8(3):421.CrossRefGoogle Scholar
  84. 84.
    Poon MC, Aledort LM, Anderle K, Kunschak M, Morfini M. Comparison of the recovery and half-life of a high-purity factor IX concentrate with those of a factor IX complex concentrate. Factor IX Study Group. Transfusion. 1995;35(4):319.CrossRefGoogle Scholar
  85. 85.
    Powell JS, Pasi KJ, Ragni MV, Ozelo MC, Valentino LA, Mahlangu JN, Josephson NC, Perry D, Manco-Johnson MJ, Apte S, Baker RI, Chan GC, Novitzky N, Wong RS, Krassova S, Allen G, Jiang H, Innes A, Li S, Cristiano LM, Goyal J, Sommer JM, Dumont JA, Nugent K, Vigliani G, Brennan A, Luk A, Pierce GF, B-LONG Investigators. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med. 2013;369(24):2313.CrossRefGoogle Scholar
  86. 86.
    Srivastava A, Brewer AK, Mauser-Bunschoten EP, Key NS, Kitchen S, Llinas A, Ludlam CA, Mahlangu JN, Mulder K, Poon MC, Street A, Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1–47.CrossRefGoogle Scholar
  87. 87.
    Djulbegovic B, Marasa M, Pesto A, Kushner GM, Hadley T, Joseph G, Goldsmith G. Safety and efficacy of purified factor IX concentrate and antifibrinolytic agents for dental extractions in hemophilia B. Am J Hematol. 1996;51(2):168.CrossRefGoogle Scholar
  88. 88.
    StajcićZ. The combined local/systemic use of antifibrinolytics in hemophiliacs undergoing dental extractions. Int J Oral Surg. 1985;14(4):339.CrossRefGoogle Scholar
  89. 89.
    Berntorp E, Shapiro AD. Modern haemophilia care. Lancet. 2012;379(9824):1447–56. Epub 2012 Mar 27.CrossRefGoogle Scholar
  90. 90.
    Kempton CL, White GC. How we treat a hemophilia A patient with a factor VIII inhibitor. Blood. 2009;113(1):11.CrossRefGoogle Scholar
  91. 91.
    Astermark J, Donfield SM, DiMichele DM, Gringeri A, Gilbert SA, Waters J, Berntorp E, FENOC Study Group. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood. 2007;109(2):546.CrossRefGoogle Scholar
  92. 92.
    Young G, Shafer FE, Rojas P, Seremetis S. Single 270 microg kg(−1)-dose rFVIIa vs. standard 90 microg kg(−1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia. 2008;14(2):287.CrossRefGoogle Scholar
  93. 93.
    Santagostino E, Mancuso ME, Rocino A, Mancuso G, Scaraggi F, Mannucci PM. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J Thromb Haemost. 2006;4(2):367.CrossRefGoogle Scholar
  94. 94.
    Kavakli K, Makris M, Zulfikar B, Erhardtsen E, Abrams ZS, Kenet G. NovoSeven trial (F7HAEM-1510) investigators. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial. Thromb Haemost. 2006;95(4):600.CrossRefGoogle Scholar
  95. 95.
    Mauser-Bunschoten EP, Zijl JA, Mali W, van Rinsum AC, van den Berg HM, Roosendaal G. Successful treatment of severe bleeding in hemophilic target joints by selective angiographic embolization. Blood. 2005;105(7):2654.CrossRefGoogle Scholar
  96. 96.
    Mazepa MA, Monahan PE, Baker JR, Riske BK, Soucie JM, US Hemophilia Treatment Center Network. Men with severe hemophilia in the United States: birth cohort analysis of a large national database. Blood. 2016;127(24):3073–81.CrossRefGoogle Scholar
  97. 97.
    Kulkarni R, Soucie JM, Evatt BL, Hemophilia Surveillance System Project Investigators. Prevalence and risk factors for heart disease among males with hemophilia. Am J Hematol. 2005;79(1):36–42.CrossRefGoogle Scholar
  98. 98.
    Chronic complications and age-related comorbidities in patients with hemophilia. UpToDate Online. Nov 17, 2016.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Aaron Strumwasser
    • 1
  • Erin Palm
    • 1
  1. 1.Los Angeles CountyUniversity of Southern California Medical CenterLos AngelesUSA

Personalised recommendations